Evaluation of metaphylactic RNA interference to prevent equine herpesvirus type 1 infection in experimental herpesvirus myeloencephalopathy in horses

Gillian A. Perkins, Gerlinde R. Van de Walle, Nicola Pusterla, Hollis N. Erb, Nikolaus Osterrieder

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective-To evaluate metaphylactic RNA interference to prevent equine herpesvirus type 1 (EHV-1) infection in experimental herpesvirus myeloencephalopathy in horses and to determine whether horses infected with a neuropathogenic strain of the virus that develop equine herpesvirus myeloencephalopathy (EHM) have differences in viremia. Animals-13 seronegative horses. Procedures-EHV-1 strain Ab4 was administered intranasally on day 0, and small interfering RNAs (siRNAs [EHV-1 specific siRNAs {n = 7} or an irrelevant siRNA {6}]) were administered intranasally 24 hours before and 12, 24, 36, and 48 hours after infection. Physical and neurologic examinations, nasal swab specimens, and blood samples were collected for virus isolation and quantitative PCR assay. Data from the study were combined with data from a previous study of 14 horses. Results-No significant difference was detected in clinical variables, viremia, or detection of EHV-1 in nasal swab specimens of horses treated with the EHV-1 targeted siRNAs (sigB3-siOri2) versus controls. No significant differences in viremia were detected between horses that developed EHM and those that did not. Conclusions and Clinical Relevance-Administration of siRNAs targeted against EHV-1 around the time of EHV-1 infection was not protective with this experimental design. Horses infected with the neuropathogenic EHV-1 strain Ab4 that developed EHM did not have a more pronounced viremia.

Original languageEnglish (US)
Pages (from-to)248-256
Number of pages9
JournalAmerican Journal of Veterinary Research
Volume74
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

myeloencephalopathy
Equid Herpesvirus 1
Equid herpesvirus 1
Herpesviridae Infections
Herpesviridae
RNA Interference
RNA interference
Horses
horses
infection
Viremia
viremia
small interfering RNA
Nose
Small Interfering RNA
Viruses
viruses
Neurologic Examination
clinical examination
Physical Examination

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Evaluation of metaphylactic RNA interference to prevent equine herpesvirus type 1 infection in experimental herpesvirus myeloencephalopathy in horses. / Perkins, Gillian A.; Van de Walle, Gerlinde R.; Pusterla, Nicola; Erb, Hollis N.; Osterrieder, Nikolaus.

In: American Journal of Veterinary Research, Vol. 74, No. 2, 02.2013, p. 248-256.

Research output: Contribution to journalArticle

@article{d601875be50045f7b80194dca71fb2af,
title = "Evaluation of metaphylactic RNA interference to prevent equine herpesvirus type 1 infection in experimental herpesvirus myeloencephalopathy in horses",
abstract = "Objective-To evaluate metaphylactic RNA interference to prevent equine herpesvirus type 1 (EHV-1) infection in experimental herpesvirus myeloencephalopathy in horses and to determine whether horses infected with a neuropathogenic strain of the virus that develop equine herpesvirus myeloencephalopathy (EHM) have differences in viremia. Animals-13 seronegative horses. Procedures-EHV-1 strain Ab4 was administered intranasally on day 0, and small interfering RNAs (siRNAs [EHV-1 specific siRNAs {n = 7} or an irrelevant siRNA {6}]) were administered intranasally 24 hours before and 12, 24, 36, and 48 hours after infection. Physical and neurologic examinations, nasal swab specimens, and blood samples were collected for virus isolation and quantitative PCR assay. Data from the study were combined with data from a previous study of 14 horses. Results-No significant difference was detected in clinical variables, viremia, or detection of EHV-1 in nasal swab specimens of horses treated with the EHV-1 targeted siRNAs (sigB3-siOri2) versus controls. No significant differences in viremia were detected between horses that developed EHM and those that did not. Conclusions and Clinical Relevance-Administration of siRNAs targeted against EHV-1 around the time of EHV-1 infection was not protective with this experimental design. Horses infected with the neuropathogenic EHV-1 strain Ab4 that developed EHM did not have a more pronounced viremia.",
author = "Perkins, {Gillian A.} and {Van de Walle}, {Gerlinde R.} and Nicola Pusterla and Erb, {Hollis N.} and Nikolaus Osterrieder",
year = "2013",
month = "2",
doi = "10.2460/ajvr.74.2.248",
language = "English (US)",
volume = "74",
pages = "248--256",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "2",

}

TY - JOUR

T1 - Evaluation of metaphylactic RNA interference to prevent equine herpesvirus type 1 infection in experimental herpesvirus myeloencephalopathy in horses

AU - Perkins, Gillian A.

AU - Van de Walle, Gerlinde R.

AU - Pusterla, Nicola

AU - Erb, Hollis N.

AU - Osterrieder, Nikolaus

PY - 2013/2

Y1 - 2013/2

N2 - Objective-To evaluate metaphylactic RNA interference to prevent equine herpesvirus type 1 (EHV-1) infection in experimental herpesvirus myeloencephalopathy in horses and to determine whether horses infected with a neuropathogenic strain of the virus that develop equine herpesvirus myeloencephalopathy (EHM) have differences in viremia. Animals-13 seronegative horses. Procedures-EHV-1 strain Ab4 was administered intranasally on day 0, and small interfering RNAs (siRNAs [EHV-1 specific siRNAs {n = 7} or an irrelevant siRNA {6}]) were administered intranasally 24 hours before and 12, 24, 36, and 48 hours after infection. Physical and neurologic examinations, nasal swab specimens, and blood samples were collected for virus isolation and quantitative PCR assay. Data from the study were combined with data from a previous study of 14 horses. Results-No significant difference was detected in clinical variables, viremia, or detection of EHV-1 in nasal swab specimens of horses treated with the EHV-1 targeted siRNAs (sigB3-siOri2) versus controls. No significant differences in viremia were detected between horses that developed EHM and those that did not. Conclusions and Clinical Relevance-Administration of siRNAs targeted against EHV-1 around the time of EHV-1 infection was not protective with this experimental design. Horses infected with the neuropathogenic EHV-1 strain Ab4 that developed EHM did not have a more pronounced viremia.

AB - Objective-To evaluate metaphylactic RNA interference to prevent equine herpesvirus type 1 (EHV-1) infection in experimental herpesvirus myeloencephalopathy in horses and to determine whether horses infected with a neuropathogenic strain of the virus that develop equine herpesvirus myeloencephalopathy (EHM) have differences in viremia. Animals-13 seronegative horses. Procedures-EHV-1 strain Ab4 was administered intranasally on day 0, and small interfering RNAs (siRNAs [EHV-1 specific siRNAs {n = 7} or an irrelevant siRNA {6}]) were administered intranasally 24 hours before and 12, 24, 36, and 48 hours after infection. Physical and neurologic examinations, nasal swab specimens, and blood samples were collected for virus isolation and quantitative PCR assay. Data from the study were combined with data from a previous study of 14 horses. Results-No significant difference was detected in clinical variables, viremia, or detection of EHV-1 in nasal swab specimens of horses treated with the EHV-1 targeted siRNAs (sigB3-siOri2) versus controls. No significant differences in viremia were detected between horses that developed EHM and those that did not. Conclusions and Clinical Relevance-Administration of siRNAs targeted against EHV-1 around the time of EHV-1 infection was not protective with this experimental design. Horses infected with the neuropathogenic EHV-1 strain Ab4 that developed EHM did not have a more pronounced viremia.

UR - http://www.scopus.com/inward/record.url?scp=84873332652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873332652&partnerID=8YFLogxK

U2 - 10.2460/ajvr.74.2.248

DO - 10.2460/ajvr.74.2.248

M3 - Article

C2 - 23363350

AN - SCOPUS:84873332652

VL - 74

SP - 248

EP - 256

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 2

ER -